| Date Filed | Type | Description |
| 08/11/2023 |
4
| MCGUIRE TERRANCE (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Sold 8 shares
@ $3.395, valued at
$27.2 |
|
| 07/28/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/19/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
8-K
| Other Events Interactive Data |
| 06/09/2023 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 06/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 05/25/2023 |
8-K
| Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ... |
| 05/23/2023 |
SC 13D/A
| Hecht Peter M has filed a Schedule 13D for Cyclerion Therapeutics, Inc. |
| 05/22/2023 |
4
| Hecht Peter M (CEO) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 225,000 shares
@ $8.68, valued at
$2M
Granted 351,037 convertible preferred
@ $0 |
|
| 05/15/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 05/12/2023 |
SC 13D/A
| Hecht Peter M has filed a Schedule 13D for Cyclerion Therapeutics, Inc. |
| 04/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/03/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
SC 13D/A
| Hecht Peter M has filed a Schedule 13D for Cyclerion Therapeutics, Inc. |
| 03/22/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/13/2023 |
SC 13G
| Slate Path Capital LP reports a 16.5% stake in Cyclerion Therapeutics, Inc. |
| 11/29/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/21/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 10/06/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
4/A
| Hyman Steven (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.|
Txns:
| Granted 57,753 options to buy
@ $0.78, valued at
$45k
|
|
| 07/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|